Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. (Q37785948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Eithne Costello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

John P Neoptolemos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

D J Naisbitt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

W Greenhalf

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

B K Park

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G W Middleton

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1007-1016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

Telomerase catalytic subunit homologs from fission yeast and human

13 February 2020

cites work

1 reference

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections

21 January 2018

1 reference

Linking functional decline of telomeres, mitochondria and stem cells during ageing

21 January 2018

1 reference

Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse

21 January 2018

1 reference

Telomerase and cancer therapeutics

21 January 2018

1 reference

Creation of human tumour cells with defined genetic elements

21 January 2018

1 reference

A survey of telomerase activity in human cancer

21 January 2018

1 reference

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

21 January 2018

1 reference

Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer

21 January 2018

1 reference

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

21 January 2018

1 reference

Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes

21 January 2018

1 reference

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

21 January 2018

1 reference

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes

21 January 2018

1 reference

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

21 January 2018

1 reference

Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma

21 January 2018

1 reference

Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT.

21 January 2018

1 reference

Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.

21 January 2018

1 reference

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

21 January 2018

1 reference

Interleukin-12: biological properties and clinical application

21 January 2018

1 reference

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

21 January 2018

1 reference

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

21 January 2018

1 reference

Antigen presentation by MHC class I and its regulation by interferon gamma

21 January 2018

1 reference

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

21 January 2018

1 reference

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

21 January 2018

1 reference

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses

21 January 2018

1 reference

Epitope spreading in immune-mediated diseases: implications for immunotherapy

21 January 2018

1 reference

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

Head and backbone of the Early Cambrian vertebrate Haikouichthys

21 January 2018

1 reference

Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses

21 January 2018

1 reference

Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.

21 January 2018

1 reference

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

21 January 2018

1 reference

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

21 January 2018

1 reference

CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.10.92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20822343%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference